Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039461 | 1.00 | NOS3 (0.37) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL9860940 | 1.00 | NOS3 (0.37) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL9740100 | 0.94 | — | — | |
| SCHEMBL9740105 | 0.94 | — | — | |
| SCHEMBL31621900 | 0.84 | NOS1 (0.37) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL11154190 | 0.81 | NOS1 (0.40) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL11154919 | 0.81 | NOS1 (0.40) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL27452592 | 0.80 | NOS1 (0.41) | NOS1NOS2ALDH1A1KDM4ENPC1 | |
| SCHEMBL28122037 | 0.80 | SMN1; SMN2 (0.43) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL6922607 | 0.79 | KMT2A (0.35) | ALDH1A1KDM4EHPGDSMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409468-B9 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1409468-B1 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-6995269-B2 | Guanidinobenzamides | CHIRON CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1409468-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6638927-B2 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl) -ethyl)-benzamide for example | CHIRON CORPORATION | 2003-10-28 | — | — | US | disclosed |
| US-20030199499-A1 | Novel guanidinobenzamides | CHIRON CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | CHIRON CORPORATION | 2002-09-26 | — | — | US | disclosed |
| WO-2002018327-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-0705308-A1 | ELECTROPHORETIC ENAMEL AND PROCESS FOR LACQUERING ELECTROCONDUCTIVE SUBSTRATES | BASF Lacke + Farben AG (DE) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000593-A2 | ELECTROPHORETIC ENAMEL AND PROCESS FOR LACQUERING ELECTROCONDUCTIVE SUBSTRATES | BASF LACKE + FARBEN AG (DE) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199499-A1 | Novel guanidinobenzamides | GUCY1B2, GPR119, GUCY1B1 | NOS3 1173/4885NOS1 569/4885NOS2 335/4885 |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | MC4R, MC5R, MC3R | NOS3 3149/4885NOS1 3123/4885NOS2 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.